...
首页> 外文期刊>American Journal of Pathology >Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors
【24h】

Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors

机译:使用人类成纤维细胞瘤的例子验证组织切片对癌症标本的免疫组织化学分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Tissue microarrays allow high-throughput molecular profiling of cancer specimens by immunohistochemistry. Phenotype information of sections from arrayed biopsies on a multitissue block needs to be representative of full sections, as protein expression varies throughout the entire tumor specimen. To validate the use of tissue microarrays for immunophenotyping, we studied a group of 59 fibroblastic tumors with variable protein expression patterns by immunohistochemistry for Ki-67, p53, and the retinoblastoma protein (pRB). Data on full tissue sections were compared to the results of one, two, and three 0.6-mm core biopsies per tumor on a tissue array. Ki-67 and p53 staining was read as two categories (positive or negative). Concordance for this staining between tissue arrays with triplicate cores per tumor and full sections were 96 and 98%, respectively. For pRB staining was read as three categories (high, moderate, or negative), where concordance was 91%. The use of three cores per tumor resulted in lower numbers of lost cases and lower nonconcordance with standard full sections as compared to one or two cores per tumor. Correlations between phenotypes and clinical outcome were not significantly different between full section and array-based analysis. Triplicate 0.6-mm core biopsies sampled on tissue arrays provide a reliable system for high-throughput expression profiling by immunohistochemistry when compared to standard full sections. Triplicate cores offer a higher rate of assessable cases and a lower rate of nonconcordant readings than one or two cores. Concordance of triplicate cores is high (96 to 98%) for two category distinction and decreases with the complexity of the phenotypes being analyzed (91%).
机译:组织微阵列可通过免疫组织化学技术对癌症标本进行高通量分子分析 。由于在整个肿瘤标本中蛋白质表达 有所不同,因此在多组织块上进行阵列活检的切片的表型信息 需要 来代表完整切片。为了验证 组织芯片用于免疫表型分析的方法,我们通过免疫组化方法研究了 一组59个具有可变蛋白表达 模式的成纤维细胞瘤,用于Ki-67 ,p53和视网膜母细胞瘤 蛋白(pRB)。将完整组织切片上的数据与组织阵列上每个 肿瘤的 一,二和三0.6 mm核心活检结果进行比较。 Ki-67和p53染色分为 两种类别(阳性或阴性)。每个肿瘤一式三份的组织阵列与完整切片 之间的染色 的一致性分别为96%和98%。对于pRB染色,读为 三种类别(高,中或阴性),其中一致性 为91%。与每个肿瘤一个或两个核心相比,每个肿瘤三个核心的使用导致更少的丢失病例数和更少的与标准完整切片的不一致性。表型与基于阵列的分析之间,表型与临床结局之间的相关性没有显着差异。与标准完整切片相比,在组织阵列上采样的三重 0.6毫米核心活检样本为通过免疫组织化学 进行高通量表达谱分析提供了可靠的 系统。与一两个核心相比,一式三份的核心提供的 可评估病例率更高,非一致性 的阅读率更低。对于两个类别的区分,一式三份的核心 的一致性很高(96%到98%),随着所分析表型的复杂性(91%)而降低了 。上>

著录项

  • 来源
    《American Journal of Pathology》 |2001年第4期|1245-1251|共7页
  • 作者单位

    Surgery,Memorial Sloan-Kettering Cancer Center, New York, New York;

    From the Departments of Pathology,Memorial Sloan-Kettering Cancer Center, New York, New York;

    Surgery,Memorial Sloan-Kettering Cancer Center, New York, New York;

    From the Departments of Pathology,Memorial Sloan-Kettering Cancer Center, New York, New York;

    From the Departments of Pathology,Memorial Sloan-Kettering Cancer Center, New York, New York;

    and Biostatistics,Memorial Sloan-Kettering Cancer Center, New York, New York;

    From the Departments of Pathology,Memorial Sloan-Kettering Cancer Center, New York, New York;

    Surgery,Memorial Sloan-Kettering Cancer Center, New York, New York;

    Surgery,Memorial Sloan-Kettering Cancer Center, New York, New York;

    From the Departments of Pathology,Memorial Sloan-Kettering Cancer Center, New York, New York;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号